| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 20, 2026 |
| Accession Number: | 0001193125-26-162823 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
SCHEDULE 13D - Alamar Biosciences, Inc. (0002104204) (Subject)
SCHEDULE 13D - Alamar Biosciences, Inc. (0002104204) (Subject)
EFFECT - Alamar Biosciences, Inc. (0002104204) (Filer)
SHANGHAI, April 20, 2026 /PRNewswire/ -- Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ Stock Exchange on April 17th, 2026, Beijing Time. Alamar (NASDAQ:ALMR) issued shares at a price of $17 per share and opened at $22.6 per share with a market capitalization of approximately $1.5 billion. Qiming Venture Partners led Alamar's Series A financing in 2020 and continued to fund the company's development in the following Series B and Series C rounds. Before the company's IPO, Qiming Venture Partners held approximately 19.2% stake in Alamar and was one of its most important institutional investors.Fo
4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
4 - Alamar Biosciences, Inc. (0002104204) (Issuer)